Literature DB >> 522906

4,4'-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man.

H Bässmann, J Böttcher, R Schüppel.   

Abstract

4,4'-Dihydroxyphenazone (4-hydroxy-1-4'-hydroxyphenyl)-2,3-dimethyl-3-pyrazoline-5-one) was isolated as a metabolite of phenazone (antipyrine) after acid hydrolysis of rat urine. This was characterized and identified by NMR, MS, IR, UV, Fp and epsilon270. After dosage with phenazone, 4,4'-dihydroxyphenazone is excreted in conjugated form by man, rabbit, guinea pig and rat. In the rat it is further shown, that conjugates of 4,4'-dihydroxyphenazone are formed by glucuronidation as well as by sulfatation. The metabolite seems to add substantially to the overall metabolic pattern of phenazone in these species.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 522906     DOI: 10.1007/BF00501230

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  11 in total

1.  [Metabolic products of amino-pyrine and related compounds in humans].

Authors:  J HALBERKANN; F FRETWURST
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1950-03

2.  The fate of antipyrine in man.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

3.  Location of functional groups in antipyrine metabolites by mass spectrometry.

Authors:  E Zietz; G Spiteller
Journal:  Biomed Mass Spectrom       Date:  1977-06

4.  Quantitation of N-demethylantipyrine in biological samples and isolation and characterization of its glucuronic acid conjugate.

Authors:  C E Hignite; C Tschanz; D H Huffman; D L Azarnoff
Journal:  Drug Metab Dispos       Date:  1978 May-Jun       Impact factor: 3.922

5.  Metabolism of antipyrine by the epoxide-diol pathway in the rat, guinea pig and human.

Authors:  M Stafford; G Kellermann; R N Stillwell; M G Horning
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-08

6.  Metabolism of drugs. LIX. A new metabolite of antipyrine.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1968-08       Impact factor: 5.858

7.  Metabolism of drugs. LXX. Further study on antipyrine metabolism.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1971-01       Impact factor: 1.645

8.  Norphenazone, a new metabolite of phenazone in human urine.

Authors:  J D Baty; D A Evans
Journal:  J Pharm Pharmacol       Date:  1973-01       Impact factor: 3.765

9.  [On the metabolism of antipyrine (phenazone) in man (author's transl)].

Authors:  E Zietz; M Eichelbaum; H J Dengler; G Spiteller
Journal:  Arzneimittelforschung       Date:  1978

10.  [Demonstration of a new reactive metabolite in metabolism of phenazone (antipyrine)].

Authors:  G Wittemann; R Schüppel
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968
View more
  6 in total

1.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

3.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Preparative isolation and purification of urinary conjugates in antipyrine metabolism in man and rat.

Authors:  J Böttcher; H Bässmann; R Schüppel; W D Lehmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

5.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.